Search

Bedaquiline

[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. … [A261861] Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.

Adenosine phosphate

Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937] … Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.

Sulfasalazine

[A255582] Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. … [A255582] Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease.

Foreskin fibroblast (neonatal)

Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. … Interestingly, it has been shown that human foreskin cells possess immunosuppressive properties, which are mediated by other processes than that reported for bone marrow/stromal stem cells [A32655].

Ribavirin

Ribavirin is added to decrease relapse rates by accelerating viral clearance early in the treatment course [A19645]. … as an adjunct therapy to various first-line and second-line combination therapies recommended for each genotypes.

Allyl-{4-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-but-2-Enyl}-Methyl-Amine

Porphobilinogen deaminase, human recombinant